Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262211141 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von María López Paraja und 8 weiteren Autor:innen. Beteiligte Einrichtung: Systemic Autoinmmune Diseases Unit, Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación S…. Hauptthemen laut MEDLINE: Molecular Targeted Therapy, Granulomatosis with Polyangiitis, Churg-Strauss Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterized by asthma, eosinophilia, and necrotizing inflammation of small- to medium-sized vessels. Accumulating evidence indicates that EGPA is a polygenic and heterogeneous disorder comprising distinct antineutrophil cytoplasmic antibody (ANCA)–defined endotypes with divergent genetic backgrounds, immune pathways, and clinical phenotypes. Its pathogenesis reflects the convergence of epithelial–alarmin signaling, type 2 inflammation, eosinophil effector mechanisms, and B-cell/autoantibody responses, with myeloperoxidase (MPO)-ANCA serving as a hallmark of the vasculitic subset. Recent advances in genomics, immunology, and multi-omics profiling have uncovered biomarkers and molecular circuits sustaining disease activity and guiding therapeutic stratification. The identification of the interleukin (IL)-5–eosinophil axis, epithelial-derived alarmins, and B-cell/IgG4 networks as central pathogenic nodes has enabled the development of targeted biologic therapies that are redefining treatment paradigms. Benralizumab (anti-IL-5Rα) has recently been approved for EGPA following the phase 3 head-to-head MANDARA trial, which demonstrated non-inferiority to mepolizumab in achieving remission (BVAS = 0 with ≤4 mg/day prednisone equivalent) at weeks 36 and 48. These results, together with the established efficacy of mepolizumab, inform practical selection between IL-5 and IL-5Rα blockade and support glucocorticoid-sparing approaches. A structured literature search (2015–2025) was conducted in PubMed, Scopus, and Web of Science to identify recent advances in epidemiology, genetics, biomarkers, and targeted therapies for EGPA. This updated review integrates molecular insights, clinical endotypes, and therapeutic innovations to outline current evidence and future precision-medicine strategies aimed at improving long-term patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Systemic Autoinmmune Diseases Unit, Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.
- Faculty of Medicina and Health Sciences, Universidad de Alcalá (UAH), 28801 Alcalá de Henares, Spain.
ORCID-Profile: Grisell Starita Fajardo, María Pilar Iranzo Alcolea, Francisco José Lirola Sánchez, Mercedes Peña Rodriguez, Andrés González García, Luis Manzano Espinosa
Zitieren
APA
López Paraja, M., Starita Fajardo, G., Donate Velasco, I., Lucena López, D., Iranzo Alcolea, M. P., Lirola Sánchez, F. J., Peña Rodriguez, M., González García, A., & Manzano Espinosa, L. (2025). Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262211141
Vancouver
López Paraja M, Starita Fajardo G, Donate Velasco I, Lucena López D, Iranzo Alcolea MP, Lirola Sánchez FJ, et al. Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262211141
BibTeX
@article{LpezParaja2025,
author = {López Paraja, María and Starita Fajardo, Grisell and Donate Velasco, Ignacio and Lucena López, David and Iranzo Alcolea, María Pilar and Lirola Sánchez, Francisco José and Peña Rodriguez, Mercedes and González García, Andrés and Manzano Espinosa, Luis},
title = {Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262211141}
}
EUVIMED